Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 15 17
Eating Disorders 36 54 42 15 71 32
Feeding and Eating Disorders 43


External Ids:

Disease Ontology 12 DOID:8670
KEGG 36 H01703
ICD9CM 34 307.50
MeSH 43 D001068
NCIt 49 C89332
SNOMED-CT 67 72366004
ICD10 32 F50 F50.9
UMLS 71 C0013473

Summaries for Eating Disorder

MedlinePlus : 42 What are eating disorders? Eating disorders are serious mental health disorders. They involve severe problems with your thoughts about food and your eating behaviors. You may eat much less or much more than you need. Eating disorders are medical conditions; they are not a lifestyle choice. They affect your body's ability to get proper nutrition. This can lead to health issues, such as heart and kidney problems, or sometimes even death. But there are treatments that can help. What are the types of eating disorders? Common types of eating disorders include Binge-eating, which is out-of-control eating. People with binge-eating disorder keep eating even after they are full. They often eat until they feel very uncomfortable. Afterward, they usually have feelings of guilt, shame, and distress. Eating too much too often can lead to weight gain and obesity. Binge-eating disorder is the most common eating disorder in the U.S. Bulimia nervosa. People with bulimia nervosa also have periods of binge-eating. But afterwards, they purge, by making themselves throw up or using laxatives. They may also over-exercise or fast. People with bulimia nervosa may be slightly underweight, normal weight, or overweight. Anorexia nervosa. People with anorexia nervosa avoid food, severely restrict food, or eat very small quantities of only certain foods. They may see themselves as overweight, even when they are dangerously underweight. Anorexia nervosa is the least common of the three eating disorders, but it is often the most serious. It has the highest death rate of any mental disorder. What causes eating disorders? The exact cause of eating disorders is unknown. Researchers believe that eating disorders are caused by a complex interaction of factors. These include genetic, biological, behavioral, psychological, and social factors. Who is at risk for eating disorders? Anyone can develop an eating disorder, but they are more common in women. Eating disorders frequently appear during the teen years or young adulthood. But people can also develop them during childhood or later in life. What are the symptoms of eating disorders? The symptoms of eating disorders vary, depending on the disorder: The symptoms of binge-eating include Eating unusually large amounts of food in a specific amount of time, such as a 2-hour period Eating even when you're full or not hungry Eating fast during binge episodes Eating until you're uncomfortably full Eating alone or in secret to avoid embarrassment Feeling distressed, ashamed, or guilty about your eating Frequently dieting, possibly without weight loss The symptoms of bulimia nervosa include the same symptoms as binge-eating, plus trying to get rid of the food or weight after binging by Purging, making yourself throw up or using laxatives or enemas to speed up the movement of food through your body Doing intensive and excessive exercise Fasting Over time, bulimia nervosa can cause health problems such as Chronically inflamed and sore throat Swollen salivary glands in the neck and jaw area Worn tooth enamel and increasingly sensitive and decaying teeth. This is caused by the exposure to stomach acid every time you throw up. GERD (acid reflux) and other gastrointestinal problems Severe dehydration from purging Electrolyte imbalance, which could be too low or too high levels of sodium, calcium, potassium and other minerals. This can lead to a stroke or heart attack. The symptoms of anorexia nervosa include Eating very little, to the point of starving yourself Intensive and excessive exercise Extreme thinness Intense fear of gaining weight Distorted body image - seeing yourself as overweight even when you are severely underweight Over time, anorexia nervosa can cause health problems such as Thinning of the bones (osteopenia or osteoporosis) Mild anemia Muscle wasting and weakness Thin, brittle hair and nails Dry, blotchy, or yellowish skin Growth of fine hair all over the body Severe constipation Low blood pressure Slowed breathing and pulse. Feeling cold all the time because of a drop in internal body temperature Feeling faint, dizzy, or weak Feeling tired all the time Infertility Damage to the structure and function of the heart Brain damage Multiorgan failure Anorexia nervosa can be fatal. Some people with this disorder die of complications from starvation, and others die of suicide. Some people with eating disorders may also have other mental disorders (such as depression or anxiety) or problems with substance use. How is eating disorders diagnosed? Because eating disorders can be so serious, it is important to seek help if you or a loved one thinks that you might have a problem. To make a diagnosis, your health care provider Will take a medical history and ask about your symptoms. It is important to be honest about your eating and exercise behaviors so your provider can help you. Will do a physical exam May do blood or urine tests to rule out other possible causes of your symptoms May do other tests to see whether you have any other health problems caused by the eating disorder. These can include kidney function tests and an electrocardiogram (EKG or ECG). What are the treatments for eating disorders? Treatment plans for eating disorders are tailored to individual needs. You will likely have a team of providers helping you, including doctors, nutritionists, nurses, and therapists. The treatments may include Individual, group, and/or family psychotherapy. Individual therapy may include cognitive behavioral approaches, which help you to identify and change negative and unhelpful thoughts. It also helps you build coping skills and change behavioral patterns. Medical care and monitoring, including care for the complications that eating disorders can cause Nutrition counseling. Doctors, nurses, and counselors will help you eat healthy to reach and maintain a healthy weight. Medicines, such as antidepressants, antipsychotics, or mood stabilizers, may help treat some eating disorders. The medicines can also help with the depression and anxiety symptoms that often go along with eating disorders. Some people with serious eating disorders may need to be in a hospital or in a residential treatment program. Residential treatment programs combine housing and treatment services. NIH: National Institute of Mental Health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to bulimia nervosa and gastroparesis, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Zinc and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

KEGG : 36 Eating disorders, which include anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED), are disorders defined by disturbances in eating behavior. Anorexia nervosa (AN) is the oldest recognized eating disorder. The salient features of this eating disorder are a relentless pursuit of thinness, accompanied by a fear of becoming fat despite being markedly underweight. In women, anorexia nervosa is associated with global endocrine dysregulation, including hypothalamic-pituitary axis dysfunction and alterations in adipokine and appetite regulating hormone levels. Bulimia nervosa (BN) is defined by eating behaviors that include episodes of binge eating which are followed by recurrent self-induced vomiting performed in an attempt to avoid weight gain from the caloric overload. Binge eating disorder (BED) is currently characterized by recurrent episodes of binge eating occurring at least twice a week for 6 months or longer. In contrast to bulimia nervosa, there are no inappropriate compensatory behaviors such as vomiting. Eating disorders frequently develop during adolescence or early adulthood, but some studies have reported their onset during childhood or later in adulthood. There is growing evidence supporting a multifactorial etiology that includes genetic, neurochemical, and physiological components for eating disorders above and beyond the more conventional theories based on psychological and sociocultural factors. Brain-derived neurotrophic factor (BDNF) plays a critical role in regulating nerves in the brain. Recent studies have provided evidence that BDNF also plays a role in regulating eating behaviors. In addition, an association between the BDNF gene polymorphism and eating disorders has been demonstrated. Other genetic risk factors for eating disorders has also been reported.

Wikipedia : 74 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 33.3 SLC6A4 PYY POMC NPY MC4R LEP
2 gastroparesis 32.6 GHRL DRD3 DRD2 CCK
3 borderline personality disorder 32.4 SLC6A4 SLC6A3 HTR2C DRD2 CRHR2 COMT
4 anorexia nervosa 32.2 SLC6A4 PYY POMC NPY MC4R LEPR
5 depression 32.0 SLC6A4 HTR2C BDNF
6 alexithymia 31.9 SLC6A4 DRD2 COMT
7 avoidant personality disorder 31.8 SLC6A4 SLC6A3 DRD3 DRD2
8 amenorrhea 31.8 POMC NPY LEP GHRL
9 social phobia 31.4 SLC6A4 DRD2 COMT CCK
10 amnestic disorder 31.3 DRD2 CNR1 BDNF
11 autism spectrum disorder 31.3 SLC6A4 SLC6A3 POMC NPY MC4R LEP
12 acute stress disorder 31.3 SLC6A4 POMC BDNF
13 obsessive-compulsive personality disorder 31.3 SLC6A4 DRD3
14 major depressive disorder 31.3 SLC6A4 SLC6A3 POMC NPY LEP HTR2C
15 personality disorder 31.3 SLC6A4 SLC6A3 HTR2C DRD3 DRD2 CRHR2
16 mental depression 31.2 SLC6A4 SLC6A3 POMC HTR2C DRD2 COMT
17 substance abuse 31.2 SLC6A4 SLC6A3 NPY DRD3 DRD2 COMT
18 postpartum depression 31.2 SLC6A4 COMT BDNF
19 agoraphobia 31.1 SLC6A4 HCRTR1 COMT
20 alcohol use disorder 31.1 SLC6A4 SLC6A3 HTR2C DRD3 DRD2 COMT
21 sexual disorder 31.1 SLC6A4 POMC HTR2C DRD2
22 kleptomania 31.0 SLC6A4 DRD2
23 celiac disease 1 30.9 PYY GHRL GCG CCK
24 oppositional defiant disorder 30.9 SLC6A4 SLC6A3 DRD2 COMT
25 somatoform disorder 30.9 SLC6A4 COMT BDNF
26 diarrhea 30.9 SLC6A4 PYY POMC CCK
27 bipolar disorder 30.9 SLC6A4 SLC6A3 LEP HTR2C DRD3 DRD2
28 adjustment disorder 30.8 SLC6A4 NPY BDNF
29 polycystic ovary syndrome 30.8 POMC LEP GHRL ADIPOQ
30 constipation 30.8 SLC6A4 PYY NPY GCG CNR1 CCK
31 hypochondriasis 30.8 SLC6A4 POMC BDNF
32 restless legs syndrome 30.8 SLC6A4 SLC6A3 POMC DRD3 DRD2 COMT
33 chronic pain 30.7 COMT CNR1
34 anovulation 30.7 LEP GHRL DRD2
35 mood disorder 30.7 SLC6A4 SLC6A3 POMC NPY HTR2C DRD3
36 anxiety 30.7 SLC6A4 SLC6A3 POMC NPY HTR2C DRD3
37 traumatic brain injury 30.7 DRD2 COMT BDNF
38 brain injury 30.7 DRD2 COMT BDNF
39 pathological gambling 30.7 SLC6A4 SLC6A3 DRD3 DRD2 COMT
40 generalized anxiety disorder 30.6 SLC6A4 SLC6A3 NPY HTR2C DRD2 COMT
41 obsessive-compulsive disorder 30.6 SLC6A4 SLC6A3 POMC NPY LEP HTR2C
42 osteoporosis 30.6 LEPR LEP GHRL CNR1 BDNF ADIPOQ
43 endogenous depression 30.6 SLC6A4 POMC NPY HTR2C COMT BDNF
44 diabetes mellitus, insulin-dependent 30.6 NPY LEPR LEP GCG ADIPOQ
45 fibromyalgia 30.6 SLC6A4 POMC NPY LEP DRD2 COMT
46 polysubstance abuse 30.6 DRD3 DRD2 COMT CNR1
47 hypothalamic obesity 30.6 LEPR LEP
48 sleep apnea 30.6 SLC6A4 LEPR LEP HTR2C GHRL BDNF
49 withdrawal disorder 30.6 POMC DRD2 CNR1
50 antisocial personality disorder 30.5 SLC6A4 SLC6A3 DRD2 COMT

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):

Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:

Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:

decrease in appetite, adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 ADIPOQ BDNF CNR1 COMT CRHR2 DRD2
2 homeostasis/metabolism MP:0005376 10.43 ADIPOQ BDNF CCK CNR1 COMT CRHR2
3 adipose tissue MP:0005375 10.37 ADIPOQ CNR1 CRHR2 DRD2 DRD3 GHRL
4 growth/size/body region MP:0005378 10.34 ADIPOQ BDNF CNR1 DRD2 DRD3 HTR2C
5 nervous system MP:0003631 10.33 ADIPOQ BDNF CCK CNR1 COMT DRD2
6 endocrine/exocrine gland MP:0005379 10.29 ADIPOQ BDNF CCK COMT CRHR2 DRD2
7 cardiovascular system MP:0005385 10.24 ADIPOQ COMT CRHR2 DRD2 DRD3 LEP
8 digestive/alimentary MP:0005381 10.18 BDNF CNR1 DRD2 DRD3 GHRL LEP
9 integument MP:0010771 10.16 ADIPOQ BDNF CNR1 DRD2 HTR2C LEP
10 normal MP:0002873 10.02 BDNF CNR1 DRD2 GHRL LEPR MC4R
11 liver/biliary system MP:0005370 9.98 ADIPOQ DRD2 LEP LEPR MC4R NPY
12 no phenotypic analysis MP:0003012 9.91 BDNF CCK CNR1 DRD2 LEPR MC4R
13 renal/urinary system MP:0005367 9.91 ADIPOQ CCK COMT DRD2 DRD3 LEP
14 respiratory system MP:0005388 9.7 ADIPOQ BDNF COMT DRD2 LEP LEPR
15 skeleton MP:0005390 9.61 ADIPOQ CNR1 DRD2 LEP LEPR MC4R
16 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Norepinephrine Approved Phase 4 51-41-2 439260
Baclofen Approved Phase 4 1134-47-0 2284
leucovorin Approved Phase 4 58-05-9 6006 143
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
Liraglutide Approved Phase 4 204656-20-2 44147092
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Acetaminophen Approved Phase 4 103-90-2 1983
Cycloserine Approved Phase 4 68-41-7 401 6234
Citalopram Approved Phase 4 59729-33-8 2771
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
Cyproheptadine Approved Phase 4 129-03-3 2913
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Raclopride Investigational Phase 4 84225-95-6
24 Astringents Phase 4
25 Narcotics Phase 4
26 Psychotropic Drugs Phase 4
27 Antidepressive Agents Phase 4
28 Narcotic Antagonists Phase 4
29 Atomoxetine Hydrochloride Phase 4
30 Adrenergic Agents Phase 4
31 Anticonvulsants Phase 4
32 Antiparkinson Agents Phase 4
33 Anti-Obesity Agents Phase 4
34 Appetite Depressants Phase 4
35 Hormone Antagonists Phase 4
36 Excitatory Amino Acid Antagonists Phase 4
37 Excitatory Amino Acids Phase 4
38 Sympathomimetics Phase 4
39 Autonomic Agents Phase 4
40 Analgesics Phase 4
41 Duloxetine Hydrochloride Phase 4
42 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
43 Antipsychotic Agents Phase 4
44 Tranquilizing Agents Phase 4
45 Dopamine Antagonists Phase 4
46 Lipid Regulating Agents Phase 4
47 Antimetabolites Phase 4
48 Serotonin Receptor Agonists Phase 4
49 calcium channel blockers Phase 4
50 Serotonin Uptake Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 689)
# Name Status NCT ID Phase Drugs
1 Effect of Zinc Supplementation on Appetite and Growth of Primary Malnourished Children Unknown status NCT03098810 Phase 4 Zinc sulphate
2 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
3 Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients Completed NCT00327834 Phase 4 atomoxetine
4 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
5 Effectiveness of Psychological Treatments for BED Completed NCT00060762 Phase 4
6 A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. Completed NCT00607789 Phase 4 Duloxetine;Placebo
7 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
8 Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders Completed NCT01493674 Phase 4
9 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
10 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
11 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
12 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
13 A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
14 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
15 Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition Completed NCT01341236 Phase 4
16 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
17 Body Contouring - the Analysis of Non-invasive and Invasive Methods and Their Interventional Effects on Quality of Life Completed NCT02151799 Phase 4
18 Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
19 Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
20 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
21 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
22 Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
23 Attenuation of Corticosteroid Induced Hippocampal Changes Completed NCT01656187 Phase 4 Memantine 10 mg capsule;Memantine-matched Placebo capsule
24 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
25 Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes Completed NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
26 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
27 Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief Completed NCT00286650 Phase 4
28 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
29 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 5 Years 6 Months of Age Recruiting NCT03815019 Phase 4 Megestrol Acetate
30 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Terminated NCT02568007 Phase 4 Cyproheptadine
31 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
32 Treatment of College Students With ADHD Using OROS Methylphenidate Withdrawn NCT00931398 Phase 4 methylphenidate HCl (Concerta);Placebo
33 Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
34 Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial Unknown status NCT01693237 Phase 2, Phase 3
35 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
36 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
37 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
38 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Armodafinil;Matching placebo
39 Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
40 An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder Completed NCT02684279 Phase 3 Dasotraline
41 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
42 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
43 A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
44 A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
45 The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
46 The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
47 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
48 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
49 Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT00307619 Phase 3 topiramate
50 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Paroxetine Hydrochloride
Sertraline Hydrochloride

Cochrane evidence based reviews: feeding and eating disorders

Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

Brain, Testes, Bone, Pituitary, Heart, Liver, Cortex

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 18442)
# Title Authors PMID Year
Anorexia nervosa in adolescents: An overview. 61 42
31568077 2019
Recent advances in therapies for eating disorders. 61 42
31598212 2019
Heavy Hunger-Managing Weight and Obesity in Black American Communities. 42
31638656 2019
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 54 61
20339027 2010
Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells. 54 61
20041293 2010
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 54 61
20195875 2010
The regulatory role of neurotensin on the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions. 54 61
19878995 2010
The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. 54 61
19852950 2010
Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. 54 61
19733621 2010
Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. 54 61
19763327 2009
Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. 54 61
19801960 2009
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 54 61
19741568 2009
Intracerebroventricular administration of leptin increases anxiety-like behavior in female rats after semi-starvation--implications for anxiety in eating disorders. 54 61
19725430 2009
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 54 61
19046818 2009
Low serum BDNF and food intake regulation: a possible new explanation of the pathophysiology of eating disorders. 54 61
19152823 2009
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 54 61
18728162 2008
Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine. 54 61
18560807 2008
Vagal and hormonal gut-brain communication: from satiation to satisfaction. 54 61
18402643 2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. 54 61
18508462 2008
Serotonin transporter binding in eating disorders. 54 61
18165910 2008
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. 54 61
18199621 2008
Ghrelin and feedback systems. 54 61
17983856 2008
[Cannabinoid system and feeding regulation]. 54 61
18551230 2008
Structure and function of ghrelin. 54 61
18193177 2008
Hormonal alteration in obese adolescents with eating disorder: effects of multidisciplinary therapy. 54 61
18547953 2008
Nutrition and fertility. 54 61
18043554 2007
Serotonin transporter binding after recovery from eating disorders. 54 61
17690869 2007
Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. 54 61
18250619 2007
Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. 54 61
17376155 2007
Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. 54 61
17768271 2007
Cannabinoids in eating disorders and obesity. 54 61
17952656 2007
Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. 54 61
17616759 2007
Roles of leptin and ghrelin in eating disorders? 54 61
17548078 2007
[Genetic polymorphism of COMT in mental disorders]. 54 61
18046978 2007
Leptin and the cardiovascular system: a review. 54 61
18221108 2007
Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. 54 61
17598965 2007
[Some neurological and psychiatric complications of the disorders of the hypothalamo-hypophyseal system]. 54 61
17437948 2007
The role of leptin in anorexia nervosa: clinical implications. 54 61
17060920 2007
Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. 54 61
18337636 2007
[Leptin and glucose metabolism in eating disorders]. 54 61
17895538 2007
HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 54 61
17691947 2007
Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. 54 61
16921495 2006
Plasma agouti-related protein levels in women with anorexia nervosa. 54 61
16904835 2006
Effect of two fasting periods of different duration on ghrelin response to a mixed meal. 54 61
17015184 2006
Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. 54 61
16969275 2006
Eating, sleeping and rewarding: orexin receptors and their antagonists. 54 61
17002215 2006
No change between the serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. 54 61
16753247 2006
The role of neurotensin in central nervous system pathophysiology: what is the evidence? 54 61
16862241 2006
Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. 54 61
16632412 2006
Emerging drugs for eating disorder treatment. 54 61
16634704 2006

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to KEGG:

# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.05 SLC6A4 SLC6A3 COMT
Show member pathways
13 10.66 CNR1 CCK
15 10.36 POMC CRHR2

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.02 PYY POMC NPY LEP GHRL GCG
2 extracellular region GO:0005576 10.02 PYY POMC NPY LEPR LEP GHRL
3 integral component of plasma membrane GO:0005887 10.01 SLC6A4 SLC6A3 HTR2C HCRTR1 DRD3 DRD2
4 dendrite GO:0030425 9.73 HTR2C DRD2 CRHR2 COMT CCK BDNF
5 GABA-ergic synapse GO:0098982 9.63 DRD3 DRD2 CNR1
6 integral component of postsynaptic membrane GO:0099055 9.61 SLC6A4 SLC6A3 DRD2
7 dopaminergic synapse GO:0098691 9.33 SLC6A3 DRD3 DRD2
8 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 DRD2 CNR1
9 axon GO:0030424 9.23 SLC6A3 GHRL DRD2 CRHR2 COMT CNR1

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.07 POMC MC4R LEP HTR2C HCRTR1 GHRL
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 HTR2C HCRTR1 GCG DRD2
3 response to hypoxia GO:0001666 9.97 SLC6A4 LEP DRD2 ADIPOQ
4 response to toxic substance GO:0009636 9.91 SLC6A4 DRD3 DRD2
5 response to drug GO:0042493 9.91 SLC6A4 SLC6A3 HTR2C DRD3 DRD2 COMT
6 circadian rhythm GO:0007623 9.9 SLC6A4 LEP ADIPOQ
7 neuropeptide signaling pathway GO:0007218 9.88 PYY POMC NPY HCRTR1
8 positive regulation of cold-induced thermogenesis GO:0120162 9.88 LEPR LEP GHRL ADIPOQ
9 regulation of insulin secretion GO:0050796 9.87 LEP GCG CNR1
10 locomotory behavior GO:0007626 9.87 SLC6A3 HTR2C DRD3 DRD2
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.86 NPY HTR2C CNR1
12 regulation of blood pressure GO:0008217 9.86 POMC NPY LEP
13 glucose metabolic process GO:0006006 9.86 LEP GHRL ADIPOQ
14 memory GO:0007613 9.86 SLC6A4 CNR1 CCK BDNF
15 response to nutrient levels GO:0031667 9.85 LEP GHRL ADIPOQ
16 response to nutrient GO:0007584 9.85 SLC6A4 LEP CNR1 ADIPOQ
17 visual learning GO:0008542 9.84 DRD3 DRD2 CCK
18 response to nicotine GO:0035094 9.83 SLC6A3 DRD2 CNR1
19 glucose homeostasis GO:0042593 9.83 POMC LEPR LEP CNR1 ADIPOQ
20 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.8 HTR2C DRD3 DRD2
21 positive regulation of multicellular organism growth GO:0040018 9.8 SLC6A3 GHRL DRD2
22 response to ethanol GO:0045471 9.8 SLC6A3 LEP DRD3 DRD2 CNR1 ADIPOQ
23 response to morphine GO:0043278 9.77 DRD3 DRD2 CNR1
24 G protein-coupled receptor signaling pathway GO:0007186 9.77 PYY POMC NPY MC4R HTR2C HCRTR1
25 response to cocaine GO:0042220 9.76 SLC6A3 DRD3 DRD2 CNR1
26 negative regulation of voltage-gated calcium channel activity GO:1901386 9.74 DRD3 DRD2
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.74 DRD3 DRD2
28 behavioral response to ethanol GO:0048149 9.73 DRD3 DRD2
29 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD3 DRD2
30 neurotransmitter biosynthetic process GO:0042136 9.73 SLC6A4 SLC6A3
31 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
32 regulation of synaptic transmission, GABAergic GO:0032228 9.73 DRD2 CNR1
33 central nervous system neuron development GO:0021954 9.72 NPY LEP
34 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
35 regulation of potassium ion transport GO:0043266 9.72 DRD3 DRD2
36 sexual reproduction GO:0019953 9.72 LEPR LEP
37 positive regulation of growth hormone secretion GO:0060124 9.71 GHRL DRD2
38 leptin-mediated signaling pathway GO:0033210 9.71 LEPR LEP
39 negative regulation of appetite GO:0032099 9.71 LEP CCK
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD3 DRD2
41 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.71 GHRL DRD2
42 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD3 DRD2
43 negative regulation of blood pressure GO:0045776 9.71 DRD3 DRD2 CNR1 ADIPOQ
44 intestinal epithelial cell differentiation GO:0060575 9.7 PYY NPY
45 dopamine catabolic process GO:0042420 9.7 SLC6A3 COMT
46 adenohypophysis development GO:0021984 9.7 SLC6A3 DRD2
47 monoamine transport GO:0015844 9.7 SLC6A4 SLC6A3
48 dopamine metabolic process GO:0042417 9.7 DRD3 DRD2 COMT
49 energy reserve metabolic process GO:0006112 9.69 MC4R LEPR LEP
50 regulation of appetite GO:0032098 9.68 POMC HTR2C

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.92 NPY MC4R HTR2C HCRTR1 DRD3 DRD2
2 G protein-coupled receptor binding GO:0001664 9.71 PYY POMC NPY GHRL
3 signaling receptor binding GO:0005102 9.7 SLC6A3 POMC NPY LEP GCG DRD2
4 neuropeptide hormone activity GO:0005184 9.61 PYY NPY CCK
5 peptide hormone binding GO:0017046 9.56 MC4R LEPR HCRTR1 CRHR2
6 dopamine binding GO:0035240 9.54 SLC6A3 DRD3 DRD2
7 peptide hormone receptor binding GO:0051428 9.52 LEP CCK
8 serotonin binding GO:0051378 9.51 SLC6A4 HTR2C
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD3 DRD2
10 monoamine transmembrane transporter activity GO:0008504 9.48 SLC6A4 SLC6A3
11 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD3 DRD2
12 drug binding GO:0008144 9.35 SLC6A3 HTR2C DRD3 DRD2 CNR1
13 hormone activity GO:0005179 9.23 PYY POMC NPY LEP GHRL GCG

Sources for Eating Disorder

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....